Ben Samelson-Jones, MD, PhD
@samelsonjones.bsky.social
Pediatric Hematologist 🧪🩸| Gene Therapist | Biochemist | 👩🦱👨👩👦🐕 Dad | Husband | Williams Syndrome Advocate
#Medsky #Hemesky
#Medsky #Hemesky
June 22, 2025 at 9:45 PM
Though pediatric #thrombosis is also distinct from adults
June 22, 2025 at 12:50 PM
Though pediatric #thrombosis is also distinct from adults
“Transformative” is a great phrasing! Thanks.
June 21, 2025 at 9:18 PM
“Transformative” is a great phrasing! Thanks.
Also on Wednesday:
SOA 22.2 - Use of bispecific antibodies for select #hemophilia B mutations
OC 69.3 - Safe multi-year bleeding reduction by AAV gene therapy in neonatal and juvenile #Hemophilia B dogs
SOA 22.2 - Use of bispecific antibodies for select #hemophilia B mutations
OC 69.3 - Safe multi-year bleeding reduction by AAV gene therapy in neonatal and juvenile #Hemophilia B dogs
June 21, 2025 at 11:57 AM
Also on Wednesday:
SOA 22.2 - Use of bispecific antibodies for select #hemophilia B mutations
OC 69.3 - Safe multi-year bleeding reduction by AAV gene therapy in neonatal and juvenile #Hemophilia B dogs
SOA 22.2 - Use of bispecific antibodies for select #hemophilia B mutations
OC 69.3 - Safe multi-year bleeding reduction by AAV gene therapy in neonatal and juvenile #Hemophilia B dogs
Start off today with
OC 03.1 - Mim8 Enhances Procoagulant Activity of Select #Hemophilia B-causing Factor IX Variants
And finish on Wednesday with
OC 69.5 - Six-year outcomes following fidanacogene elaparvovec in adults with #hemophilia B
OC 03.1 - Mim8 Enhances Procoagulant Activity of Select #Hemophilia B-causing Factor IX Variants
And finish on Wednesday with
OC 69.5 - Six-year outcomes following fidanacogene elaparvovec in adults with #hemophilia B
June 21, 2025 at 11:57 AM
Start off today with
OC 03.1 - Mim8 Enhances Procoagulant Activity of Select #Hemophilia B-causing Factor IX Variants
And finish on Wednesday with
OC 69.5 - Six-year outcomes following fidanacogene elaparvovec in adults with #hemophilia B
OC 03.1 - Mim8 Enhances Procoagulant Activity of Select #Hemophilia B-causing Factor IX Variants
And finish on Wednesday with
OC 69.5 - Six-year outcomes following fidanacogene elaparvovec in adults with #hemophilia B